Celltrion USA will take over the production facility from Eli Lilly for 460 billion won ($330 million) and aims to complete the deal by the end of this year, the company said in a press release, reports Yonhap news agency. By establishing a local production hub, Celltrion said it has created a one-stop supply chain in the United States that spans the entire drug manufacturing process, from production to commercialization. The company plans to invest 700 billion won in the plant, including the acquisition cost, and an additional 700 billion won for expansion. The Branchburg facility is a large-scale, U.S. Food and Drug Administration (FDA)-approved drug substance manufacturing site compliant with current good manufacturing practice (cGMP) regulations. "We will continue manufacturing pharmaceuticals for Lilly under a CMO agreement at the facility, while also producing Celltrion products there," Seo said.